From regional perspective, 15 regions have outgrown the IPM growth
The Indian pharma market clocked Rs 7928 crores in June 2015. It has grown at 14.8 per cent in the same month. Amongst the top 10 corporates, Sun grew by 27.9 per cent followed by Pfizer at 20.2 per cent and Abbott at 19 per cent. 23 corporates have crossed the growth of IPM amongst top 50. Wockhardt has the highest growth of 36.2 per cent followed by AstraZeneca at 35.4 per cent and Glenmark at 34.5 per cent. 27 corporate showed growths more than 10 per cent amongst the top 50.
Amongst the 11-20 ranked corporate, Glenmark has the highest growth of 34.5 per cent followed by Torrent at 28.3 per cent and USV at 27.1 per cent. Amongst the 21-30 ranked corporate, Wockhardt has the highest growth at 36.2 per cent followed by MSD 31.6 per cent and Unichem at 20.5 per cent. Amongst the 31-40 ranked corporates, AstraZeneca has the highest growth at 35.4 per cent followed by Akumentis at 33.4 per cent and JBCPL at 27 per cent. Amongst the 41-50 ranked corporates, Hetero has the highest growth at 21 per cent followed by Fourrts at 17.9 per cent and Allergan at 17.8 per cent. Amongst the 51-60 ranked corporates, Boehringer grew at 79.1 per cent followed by Eli Lilly at 39.9 per cent and Troikaa at 38.4 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 38.8 per cent followed by RPG at by 36.1 per cent followed by TTK at 26.3 per cent. AstraZeneca has entered the Rs 500 crore-club, Hetero Rs 400 crore, Troikaa Rs 300 crore, Tablets India Rs 200 crores on MAT Basis.
Amongst the top 10, Sun Pharma grew by 32.9 per cent followed by Ranbaxy at 20.5 per cent and Pfizer at 20.2 per cent. 25 companies have crossed the growth of IPM for June 2015 amongst top 50. Amongst the 11-20 ranked companies, Glenmark has the highest growth of 34.5 per cent followed by Torrent at 28.3 per cent and USV at 27.1 per cent. Amongst the 21-30 ranked companies, Wockhardt has the highest growth at 36.2 per cent followed by Unichem 20.5 per cent and Novo Nordisk at 18.9 per cent.
Indian companies have grown at 14.5 per cent versus 15.7 per cent for MNCs in June 2015. Amongst the top 50 in MNCs, AstraZeneca at 35.4 per cent , MSD grew by 31.6 per cent followed by and Merck at 22.4 per cent. Under the Non-NLEM category Indian companies grew at 4.3 per cent whereas MNCs grew at 9.4 per cent.
The DPCO containing molecules market grew at 5.6 per cent whereas the Non DPCO market grew by 16.2 per cent and Non -Sch Para 19 Market at 14.6 per cent resulting in an overall growth of 14.8 per cent for June 2015. NLEM and Non-NLEM Category showed unit growth at -0.1 per cent and 6.2 per cent respectively. The Non-Sch Para 19 market grew at 11.7 per cent from units perspective.
The DPCO 2013 portfolio for Pfizer grew at 17.4 per cent, Ranbaxy 31.9 per cent, GSK at -1.8 per cent and Abbott 11.7 per cent.
From therapy perspective, 11 therapies have outgrown the IPM growth. The respiratory market grew at 15.4 per cent, gastrointestinal market grew at 15.8 per cent, pain and analgesics market grew at 10.5 per cent whereas anti-infectives grew at 3.2 per cent. The anti-diabetic market grew at 27.4 per cent and cardiac at 18.9 per cent in chronic business. The derma market grew by 19.3 per cent and the urology market at 23.5 per cent.
From regional perspective, 15 regions have outgrown the IPM growth. The north Andhra Pradesh (AP) market grew the highest at 25.8 per cent followed by Jharkhand market at 25.3 per cent and south AP market at 20.7 per cent. No region had negative growth in June 2015.
Amoxycillin + Clavulanic Acid Market grew at 1.3 per cent whereas Glimepiride + Metformin grows at 17.5 per cent at number two. The markets of paracetamol grew at -0.2 per cent, Atorvastatin 12.1 per cent, Probiotic Microbes at 26.3 per cent, Cefixime -2.6 per cent, Pantoprazole 18.7 per cent, Montelukast + Levocetrizine at 23.6 per cent, Glimepiride + Metformin + Pioglitazone at 22.4 per cent, Vitamin-D at 30.6 per cent, Hydroquinone + Mometasone + Tretinoin at 10.3 per cent, Voglibose + Metformin + Glimepiride at 59.3 per cent, Rosuvastatin at 29.2 per cent, protein supplements at 24.1 per cent, Azithromycin at -3.8 per cent.
Mixtard leads the pack with Rs 40 crore followed by Glycomet-GP at Rs 28 crore and Spasmoproxyvon Plus at Rs 26 crore for June 2015. Phensedyl Cough grew by 189.6 per cent followed by Janumet at 132.9 per cent, Corex at 38.7 per cent, Mixtard at 33.8 per cent, Lantus at 32.4 per cent and Glycomet-GP at 22.5 per cent amongst the top 10 brands.
Few brands who have gained ranks include Chymoral Forte, Phensedyl Cough (+77), Janumet (+76), Betnesol (+75), Eltroxin (+73), Synflorix (+69), Januvia (+49), Pantocid D SR (+41), Shelcal, Jalra M (+39), Panderm Plus (+35),Spasmo Proxyvon Plus (+33), Istamet (+32), Huminsulin , Aztor (+31), Vertin (+29), Budecort (+26), Magnex (+25), Gelusil MPS , Jalra (+21), Zoryl M (+20), Levipil, Omez, Galvus, Glycomet (+18), Rosuvas, Ultracet (+13), Gemcal (+8), amongst top 100 Brands over June 2014.
Brands that have moved up ranks fastest into Top 300 brands for the month of June 2015 are Biovac C, Brilinta, Oframax, Monocef SB, Mero, Bevon, Razo D, Renerve Plus amongst others
A total of 273 brands and 462 SKUs were launched in June 2015. Top new brands for June 2015 are Rthrombo, Zita Plus and Infimab. Teneligliptin launch under the brand names of Zita Plus an Ziten from Glenmark is seen in the Gliptin space under OAD segment.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
Comments are closed.